AUTL
Autolus Therapeutics Ltd
NASDAQ: AUTL · HEALTHCARE · BIOTECHNOLOGY
$1.41
+0.00% today
Updated 2026-04-30
Market cap
$375.26M
P/E ratio
—
P/S ratio
347.95x
EPS (TTM)
$-1.08
Dividend yield
—
52W range
$1 – $3
Volume
1.7M
Autolus Therapeutics Ltd (AUTL) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
-6,571.00%
ROE
-29.60%
ROA
-22.30%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2015 | $94112.00 | $-7.46M | 100.00% | -8,613.76% | -7,931.14% |
| 2016 | $1.21M | $-12.55M | 60.56% | -1,186.14% | -1,035.48% |
| 2017 | $1.69M | $-19.73M | 40.40% | -1,383.23% | -1,165.21% |
| 2018 | $1.05M | $-31.11M | -4,520.40% | -5,503.74% | -2,976.49% |
| 2018 | $1.05M | $-31.11M | -4,520.40% | -5,503.74% | -2,976.49% |
| 2019 | $2.91M | $-123.85M | -3,525.10% | -8,513.76% | -4,258.91% |
| 2020 | $1.72M | $-142.09M | -7,765.19% | -17,675.39% | -8,285.36% |
| 2021 | $1.51M | $-142.10M | 100.00% | -9,314.80% | -9,429.06% |
| 2022 | $6.19M | $-148.84M | 100.00% | -2,306.96% | -2,402.95% |
| 2023 | $1.70M | $-208.38M | 100.00% | -10,583.10% | -12,272.26% |
| 2024 | $10.12M | $-220.66M | -1,293.48% | -2,385.63% | -2,180.45% |
| 2025 | $75.56M | $-287.53M | -27.83% | -372.45% | -380.51% |